FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2061708045> ?p ?o ?g. }

• W2061708045 endingPage "175" @default.
• W2061708045 startingPage "168" @default.
• W2061708045 abstract "The once daily, single-tablet regimen (STR) combining rilpivirine (RPV), emtricitabine (FTC), and tenofovir disoproxil fumarate (TDF) provides a simplified treatment option for antiretroviral therapy (ART)-naïve patients with baseline HIV-1 RNA (BLVL) of ≤100,000 copies/mL. The aim of this analysis is to compare long-term efficacy, safety, and tolerability of RPV+FTC/TDF vs. efavirenz (EFV)+FTC/TDF as individual components in subjects with BLVL ≤100,000 copies/mL. Week 96 efficacy and safety data from subjects with BLVL ≤100,000 copies/mL, who received daily RPV 25 mg or EFV 600 mg with FTC/TDF in the phase 3, randomized, double-blind, double-dummy, active-controlled, registrational trials ECHO and THRIVE, were analyzed. Virologic response was evaluated by intent-to-treat, time to loss of virological response (ITT-TLOVR), and Snapshot algorithms. Through Week 96, RPV+FTC/TDF demonstrated non-inferior efficacy to EFV+FTC/TDF (84% vs. 81%, respectively; ITT-TLOVR) in 543 subjects with BLVL ≤100,000 copies/mL, and overall rates of virologic failure (VF) were 5.9% vs. 2.4%, respectively. Resistance development was lower in Year 2 than Year 1. Subjects in both arms with suboptimal adherence (≤95%) had lower virologic responses (63% vs. 62%, respectively). Treatment with RPV+FTC/TDF was associated with significantly fewer treatment-related adverse events (AEs), grade 2–4 AEs, neurological and psychiatric AEs (including dizziness and abnormal dreams/nightmares), and rash. Additionally, grade 2–4 treatment-emergent laboratory abnormalities and grade 1–3 lipid abnormalities were significantly less common with RPV+FTC/TDF than EFV+FTC/TDF. RPV+FTC/TDF demonstrated non-inferior efficacy to EFV+FTC/TDF in ART-naïve subjects with BLVL ≤100,000 copies/mL and was associated with a higher rate of VF but a more favorable safety and tolerability profile through Week 96." @default.
• W2061708045 created "2016-06-24" @default.
• W2061708045 creator A5003069757 @default.
• W2061708045 creator A5004474608 @default.
• W2061708045 creator A5007893042 @default.
• W2061708045 creator A5013078758 @default.
• W2061708045 creator A5013635949 @default.
• W2061708045 creator A5018848186 @default.
• W2061708045 creator A5020826937 @default.
• W2061708045 creator A5025427459 @default.
• W2061708045 creator A5027160485 @default.
• W2061708045 creator A5030772735 @default.
• W2061708045 creator A5032649947 @default.
• W2061708045 creator A5037765362 @default.
• W2061708045 creator A5046013916 @default.
• W2061708045 creator A5064822409 @default.
• W2061708045 creator A5073460580 @default.
• W2061708045 creator A5090886714 @default.
• W2061708045 date "2014-04-01" @default.
• W2061708045 modified "2023-09-27" @default.
• W2061708045 title "Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis" @default.
• W2061708045 cites W2061817517 @default.
• W2061708045 cites W2062900531 @default.
• W2061708045 cites W2099826019 @default.
• W2061708045 cites W2142538462 @default.
• W2061708045 cites W2322864883 @default.
• W2061708045 cites W2323342869 @default.
• W2061708045 cites W55384331 @default.
• W2061708045 doi "https://doi.org/10.1089/apc.2013.0310" @default.
• W2061708045 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3985528" @default.
• W2061708045 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24660840" @default.
• W2061708045 hasPublicationYear "2014" @default.
• W2061708045 type Work @default.
• W2061708045 sameAs 2061708045 @default.
• W2061708045 citedByCount "27" @default.
• W2061708045 countsByYear W20617080452014 @default.
• W2061708045 countsByYear W20617080452015 @default.
• W2061708045 countsByYear W20617080452016 @default.
• W2061708045 countsByYear W20617080452017 @default.
• W2061708045 countsByYear W20617080452018 @default.
• W2061708045 countsByYear W20617080452019 @default.
• W2061708045 countsByYear W20617080452020 @default.
• W2061708045 countsByYear W20617080452021 @default.
• W2061708045 crossrefType "journal-article" @default.
• W2061708045 hasAuthorship W2061708045A5003069757 @default.
• W2061708045 hasAuthorship W2061708045A5004474608 @default.
• W2061708045 hasAuthorship W2061708045A5007893042 @default.
• W2061708045 hasAuthorship W2061708045A5013078758 @default.
• W2061708045 hasAuthorship W2061708045A5013635949 @default.
• W2061708045 hasAuthorship W2061708045A5018848186 @default.
• W2061708045 hasAuthorship W2061708045A5020826937 @default.
• W2061708045 hasAuthorship W2061708045A5025427459 @default.
• W2061708045 hasAuthorship W2061708045A5027160485 @default.
• W2061708045 hasAuthorship W2061708045A5030772735 @default.
• W2061708045 hasAuthorship W2061708045A5032649947 @default.
• W2061708045 hasAuthorship W2061708045A5037765362 @default.
• W2061708045 hasAuthorship W2061708045A5046013916 @default.
• W2061708045 hasAuthorship W2061708045A5064822409 @default.
• W2061708045 hasAuthorship W2061708045A5073460580 @default.
• W2061708045 hasAuthorship W2061708045A5090886714 @default.
• W2061708045 hasBestOaLocation W20617080452 @default.
• W2061708045 hasConcept C126322002 @default.
• W2061708045 hasConcept C142462285 @default.
• W2061708045 hasConcept C159047783 @default.
• W2061708045 hasConcept C197934379 @default.
• W2061708045 hasConcept C2778375690 @default.
• W2061708045 hasConcept C2778723075 @default.
• W2061708045 hasConcept C2779778239 @default.
• W2061708045 hasConcept C2781413609 @default.
• W2061708045 hasConcept C2781432083 @default.
• W2061708045 hasConcept C2993143319 @default.
• W2061708045 hasConcept C3013748606 @default.
• W2061708045 hasConcept C71924100 @default.
• W2061708045 hasConceptScore W2061708045C126322002 @default.
• W2061708045 hasConceptScore W2061708045C142462285 @default.
• W2061708045 hasConceptScore W2061708045C159047783 @default.
• W2061708045 hasConceptScore W2061708045C197934379 @default.
• W2061708045 hasConceptScore W2061708045C2778375690 @default.
• W2061708045 hasConceptScore W2061708045C2778723075 @default.
• W2061708045 hasConceptScore W2061708045C2779778239 @default.
• W2061708045 hasConceptScore W2061708045C2781413609 @default.
• W2061708045 hasConceptScore W2061708045C2781432083 @default.
• W2061708045 hasConceptScore W2061708045C2993143319 @default.
• W2061708045 hasConceptScore W2061708045C3013748606 @default.
• W2061708045 hasConceptScore W2061708045C71924100 @default.
• W2061708045 hasIssue "4" @default.
• W2061708045 hasLocation W20617080451 @default.
• W2061708045 hasLocation W20617080452 @default.
• W2061708045 hasLocation W20617080453 @default.
• W2061708045 hasLocation W20617080454 @default.
• W2061708045 hasOpenAccess W2061708045 @default.
• W2061708045 hasPrimaryLocation W20617080451 @default.
• W2061708045 hasRelatedWork W1841555244 @default.
• W2061708045 hasRelatedWork W2027284363 @default.
• W2061708045 hasRelatedWork W2093503064 @default.
• W2061708045 hasRelatedWork W2099826019 @default.
• W2061708045 hasRelatedWork W2433950280 @default.
• W2061708045 hasRelatedWork W2619517028 @default.

• next